Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant (EGESTA)

22. november 2017 oppdatert av: David B. Stewart, MD, FACS, FASCRS, Milton S. Hershey Medical Center

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota

The objectives/specific aims of this study are three-fold. First, the study seeks to evaluate the safety of fecal microbiota transplant (FMT) in patients with severe, complicated C. difficile infection (scCDI). Second, the study seeks to evaluate whether fecal microbiota transplant (FMT) can improve scCDI, with "improve" defined as either decreasing the severity of CDI, or by resolving the infection altogether. Third, the study seeks to further study the mechanism by which FMT improves the course of scCDI by performing 16S rRNA and ITS sequencing on pre-FMT and serial post-FMT stool samples in order to measure changes to bacterial and fungal microbiota as a consequence of CDI and FMT therapy. FMT material (hereafter referred to as FMTm) would be obtained from OpenBiome. FMTm is prepared from prescreened healthy donors.

The hypothesis of the study is that FMT is a preferred salvage therapy for scCDI as compared to (1) ongoing, failing medical therapy with conventional antibiotics and (2) surgery.

Studieoversikt

Status

Tilbaketrukket

Detaljert beskrivelse

The objectives/specific aims of this study are three-fold. First, the study seeks to evaluate the safety of fecal microbiota transplant (FMT) in patients with severe, complicated C. difficile infection (scCDI). Second, the study seeks to evaluate whether fecal microbiota transplant (FMT) can improve scCDI, with "improve" defined as either decreasing the severity of CDI, or by resolving the infection altogether. Third, the study seeks to further study the mechanism by which FMT improves the course of scCDI by performing 16S rRNA and ITS sequencing on pre-FMT and serial post-FMT stool samples in order to measure changes to bacterial and fungal microbiota as a consequence of CDI and FMT therapy. FMT material (hereafter referred to as FMTm) would be obtained from OpenBiome. FMTm is prepared from prescreened healthy donors.

The hypothesis of the study is that FMT is a preferred salvage therapy for scCDI as compared to (1) ongoing, failing medical therapy with conventional antibiotics and (2) surgery.

The standard of care treatment for scCDI is conventional antibiotics with either parenteral/oral metronidazole, and/or vancomycin provided in the form of oral and/or retention enemas. The reliability of these conventional antibiotics in the setting of scCDI is very unpredictable, and patients with CDI of this severity have a mortality rate that in some series is greater than 50%. It is against the mediocre historical record of these antibiotics that FMT would be tested in this highly moribund patient population.

FMT would not be provided to patients with scCDI off protocol.

Studietype

Intervensjonell

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17078
        • David Stewart

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults between 18 years of age and 75 years of age.
  • Have CDI defined as clinical symptoms of CDI (diarrhea with or without abdominal pain/abdominal distention) with a confirmatory nucleic acid amplification test (NAAT) positive for CDI.
  • Have severe/complicated disease as defined by ACG guidelines(appendix 1), with any of the following attributable to CDI:

    • Admission to intensive care unit for CDI
    • Hypotension (systolic blood pressure < 90 mmHg) with or without required use of vasopressors
    • Fever ≥ 38.5 ° C
    • Ileus (as defined by the absence of intestinal function for at least 24 hours and/or radiographic evidence of pathologically dilated small intestine without evidence of a mechanical obstruction) or significant abdominal distention
    • Mental status changes
    • WBC ≥ 35,000 cells / mm 3 or < 2,000 cells / mm 3
    • Serum lactate levels >2.2 mmol / l
    • End organ failure (mechanical ventilation,renal failure as defined by a rise in creatinine of >1.5 mg/dL either above the upper limit of normal for creatinine, or > 1.5 mg/dL from premorbid levels if that information is known, acute hepatic dysfunction as defined by an increase in AST or ALT to twice the upper limit of normal, etc.)

Exclusion Criteria:

  • Pregnant or lactating women
  • Prisoners
  • Patients under the age of 18 or over the age of 76 years of age
  • Patients who are immunocompromised including but not limited to:

    • Have HIV infection historically reported, regardless of CD4 count
    • AIDS as defined by either an AIDS-defining diagnosis (appendix 2) or a CD4 count <200/mm3,
    • Inherited or primary immune disorders,
    • Received chemotherapy within the previous 90 days, or
    • Current or recent treatment with any immunosuppressant medications in the past 90 days
  • Individuals who have received FMT at any time before potential study enrollment
  • Patients who do not have a stool test confirming C. difficile infection
  • Patients who have a severe anaphylactic response to food
  • Patients with allergies to sodium chloride or glycerol, both ingredients Generally Recognized As Safe (GRAS)
  • Patients who have colorectal cancer
  • Diagnosis of Irritable Bowel Disease or Irritable Bowel Syndrome
  • Any other condition for which the Principal Investigator thinks the treatment may pose a health risk
  • Anticipated or predicted death within the time period of follow-up for reasons unrelated to CDI
  • An APACHE II score >29 at the time of evaluation for inclusion in the study protocol (Appendix 4.0)
  • Mandatory ongoing antibiotic use for non-CDI infection
  • Patients unable to provide informed consent or who do not have a legally authorized representative for consent
  • Patients unable to comply with requirements of this study protocol

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: fecal microbiota transplant
250 mL of fecal transplant material by enema as treatment
Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
Andre navn:
  • FMT Microbiota Preparation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety - adverse events
Tidsramme: Thirty days after treatment
Absence of unexpected related adverse events
Thirty days after treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy (Cure of infection, or decrease in severity of infection based on white blood cell count)
Tidsramme: Thirty days after treatment
Cure of infection, or decrease in severity of infection based on white blood cell count
Thirty days after treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. september 2016

Primær fullføring (Faktiske)

14. november 2017

Studiet fullført (Faktiske)

14. november 2017

Datoer for studieregistrering

Først innsendt

11. november 2016

Først innsendt som oppfylte QC-kriteriene

17. november 2016

Først lagt ut (Anslag)

18. november 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. november 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. november 2017

Sist bekreftet

1. november 2017

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • STUDY00005388

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere